What question did this study set out to answer?

This research explores how MYCN contributes to tumor formation and therapeutic challenges in pediatric high-grade gliomas.

June 15, 2026Cell ReportsOpen Access

MYCN drives pediatric glioma transformation from neural progenitors and creates distinct therapeutic vulnerabilities

View Full Paper

Ask AI

Bookmark

This research explores how MYCN contributes to tumor formation and therapeutic challenges in pediatric high-grade gliomas.
Investigated the role of MYCN, Trp53, and Pten in driving tumorigenesis in high-grade gliomas.
Assessed the effects of PI3K and mTOR inhibitors on tumor response and adaptive resistance mechanisms.
Examined the impact of insulin-like growth factor signaling on treatment resistance.
MYCN, in cooperation with Trp53 and Pten loss, initiates tumorigenesis in pediatric gliomas.
Adaptive resistance occurs through MYCN rebound, countering PI3K and mTOR inhibitors due to insulin signaling.
Combining MYCN suppression with insulin receptor inhibitors enhances treatment efficacy.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial investigates MYCN pathways and therapeutic vulnerabilities in pediatric high-grade gliomas, indicating potential for targeted treatments.

Cite This Study

Gatesman et al. (2026) studied this question.

synapsesocial.com/papers/6a2f966ca1cfeec490827df2 https://doi.org/10.1016/j.celrep.2026.117522

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial investigates MYCN pathways and therapeutic vulnerabilities in pediatric high-grade gliomas, indicating potential for targeted treatments.

MYCN drives pediatric glioma transformation from neural progenitors and creates distinct therapeutic vulnerabilities

Key Points

Discussion

Implication

Cite This Study

MYCN drives pediatric glioma transformation from neural progenitors and creates distinct therapeutic vulnerabilities

Key Points

Discussion

Implication

Cite This Study